Clindamycin Phosphate is the phosphate salt form of clindamycin, a semi-synthetic, chlorinated broad-spectrum antibiotic produced by chemical modification of lincomycin. Clindamycin phosphate (Clindamycin 2-dihydrogen phosphate) is used in topical preparations.

Clindamycin (Sobelin) dissociates peptidyl-tRNA from the bacterial ribosome, thereby disrupting bacterial protein synthesis. Clindamycin is a semisynthetic broad-spectrum antibiotic produced by chemical modification of the parent compound lincomycin.

Clindamycin hydrochloride (Clinimycin HCl) inhibits protein synthesis by acting on the 50S ribosomal. It is the hydrochloride salt form of clindamycin, a semi-synthetic, chlorinated broad-spectrum antibiotic produced by chemical modification of lincomycin. Clindamycin hydrochloride(Clinimycin HCl) is used as a solid in capsules.

Clindamycin phosphate hydrochloride (Clindamycin 2-phosphate), a broad-spectrum bacteriostatic lincosamide antibiotic, serves as a prodrug of Clindamycin. It lacks antimicrobial activity in vitro; however, through phosphatase ester hydrolysis, it is rapidly converted to the active form, Clindamycin, in vivo. This compound is utilized in the research of acne and bacterial vaginosis [1] [2] [3].

Clindamycin hydrochloride monohydrate (Clindamycin alcoholate) is a protein synthesis inhibitor used orally, capable of diminishing virulence factor expression in Staphylococcus aureus at sub-minimum inhibitory concentrations (sub-MICs). It acts by suppressing Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1), and alpha-haemolysin (Hla) production. Resistance to this compound emerges through enzymatic methylation at the antibiotic's 50S ribosomal subunit binding site (23S rRNA).